Novo Nordisk A/S
NONOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | -1.56 | 2.16 | 2.29 |
| FCF Yield | 2.53% | 2.25% | 2.99% | 2.86% |
| EV / EBITDA | 20.69 | 28.13 | 28.14 | 25.96 |
| Quality | ||||
| ROIC | 38.99% | 54.20% | 49.42% | 43.62% |
| Gross Margin | 84.67% | 84.60% | 83.92% | 83.20% |
| Cash Conversion Ratio | 1.20 | 1.30 | 1.42 | 1.15 |
| Growth | ||||
| Revenue 3-Year CAGR | 17.95% | 18.16% | 11.71% | 4.89% |
| Free Cash Flow Growth | -0.50% | 9.17% | 34.69% | 59.41% |
| Safety | ||||
| Net Debt / EBITDA | 0.63 | 0.11 | 0.17 | 0.25 |
| Interest Coverage | 78.26 | 138.80 | 197.91 | 202.92 |
| Efficiency | ||||
| Inventory Turnover | 1.09 | 1.12 | 1.17 | 1.21 |
| Cash Conversion Cycle | 208.27 | 181.60 | 231.54 | 287.19 |